Study finds new blood test for heart disease risk:
This article was originally published in Clinica
Executive Summary
Levels of an enzyme in the blood could lead to a more accurate test for heart attack risk, according to a study published in The New England Journal of Medicine (October 23). Testing 604 patients for the enzyme myeloperoxidase predicted the early risk of myocardial infarction, as well as the risk of major adverse cardiac events, even when patients tested negative for Troponin T, said researchers at the Cleveland Clinic Foundation, Ohio.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.